Active Project Reports Statistics
Active Project Reports Statistics
|
Content Section
|
Details for A Cost Effectiveness Model of Disease Modifying Therapies for the Treatment of Multiple Sclerosis (MS)
|
Shown below are the details for the item you selected from the list.
| Title |
A Cost Effectiveness Model of Disease Modifying Therapies for the Treatment of Multiple Sclerosis (MS) |
| Project Number |
CMS-IA-05-28A-1 |
| Project Officr(s) |
Penny Mohr |
| Start Date |
October 2004 |
| End Date |
October 2006 |
| Funding |
$95,693 |
| Award |
Intra-agency Agreement |
| Principal Investigator(s) |
Paul Tappenden , Ph.D. |
| Awardee Name |
Sheffield University School of Health and Related Research |
| Awardee Street |
Regent Court 30, Regent Street |
| Awardee City/State/Zip |
Sheffield, UK S1 4DA |
| Description |
The purpose of this task order is to examine the incremental cost-effectiveness of self-administered medications (Copaxone, Betaseron, Rebif) relative to Avonex or best supportive care for the treatment of Multiple Sclerosis (MS) among Medicare beneficiaries. The self-administered medications listed are covered under a Medicare demonstration program mandated by Section 641 of the Medicare Prescription Drug Improvement and Modernization Act (MMA). Avonex is currently covered under Medicare Part B. An analysis of the cost-effectiveness of the demonstration project that extends coverage to these therapies is required under the MMA. |
| Status |
A final report was completed in October 2006 is available through the CMS project officer. Contact Penny Mohr at 410-786-6502. |
| | | Downloads |
There are no Downloads
| | Related Links Inside CMS |
There are no Related Links Inside CMS
| | Related Links Outside CMS |  |
There are no Related Links Outside CMS
|
|
Last Modified Date : 02/15/2008
Help with File Formats and Plug-Ins
|
Email
Print